相关实验视频

Updated: Sep 8, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

在J-ALEX研究中对与alectinib相关的基因变异进行血cfDNA分析

H Sakaguchi¹, R Katayama², M Matsumoto³

¹Department of Medical Oncology, Kanazawa University Hospital, Kanazawa, Japan.

|September 5, 2025

概括

在非小细胞肺癌 (NSCLC) 中检测血细胞自由DNA (cfDNA) 中的瘤激酶 (ALK) 突变可以预测对alectinib的耐药性. 这些突变的早期识别可以个性化治疗以获得更好的结果.

科学领域:

癌症学
遗传学
分子生物学

背景情况:

阿莱克提尼布是对非小细胞肺癌 (NSCLC) 的标准一线治疗.
对alectinib的耐药性在治疗ALK重组NSCLC方面构成重大临床挑战.
了解耐药机制对于改善患者的结果至关重要.

研究的目的:

通过下一代无血细胞DNA (cfDNA) 测序 (NGS) 来研究ALK重组NSCLC中的alectinib耐药机制.
识别特定的ALK二次突变 (SMs) 和与耐药性相关的其他遗传变异.
评估可检测的SM和无进展生存期 (PFS) 之间的相关性.

主要方法:

在J-ALEX研究中,从67名接受过alectinib治疗的患者收集了多个时间点的血样本.
对提取的cfDNA进行了下一代测序 (NGS),以检测ALK SM和其他与耐药性相关的突变.
在患有和没有可检测的MS的患者中比较了无进展生存期 (PFS).

主要成果:

在13%的患者中发现了对alectinib耐药的ALKSM,包括已知的耐药突变,如L1196M和G1202R.
与没有MS的患者相比,可检测的SM患者的PFS显著较短 (15. 2个月).
还发现了其他可操作的突变,如MET放大和KRAS/ NRAS突变,KRAS/ NRAS可能与初级耐药性有关.

结论:

通过NGS进行血cfDNA分析是识别NSCLC中alectinib耐药机制的一种可行的方法.
早期发现与耐药性相关的突变可以为个性化治疗策略提供信息.
需要进一步的前性研究来验证这些发现及其临床实用性.

关键词:

通过ALK重新排列的非小细胞肺癌亚莱克提尼血cfDNA分析电阻机制

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...